An Exploratory Study of Golidocitinib in Adult Patients With ITP

Inclusion Criteria

• •Male and female participants between 18 and 80 years old.
• •Primary ITP for \>3 months.
• •An average of two platelet counts (⩾ 7 days apart) of \< 30 × 10⁹/L.
• •Have relapsed or treatment-resistant to previous ITP therapies, including corticosteroids and at least one other ITP therapy.
• •Have history of response to previous treatments.
• •Adequate hematologic, hepatic, and renal fuction.
• •Participants willing to comply with contraceptive restrictions.